Flmodafinil — Safety, Research, Risks & Legal Status

Not medical advice. Flmodafinil is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Fluorafinil, flmodafinil, 2-(dipropylaminophenethyl) disulfide
Category	Research Chemical
modafinil_analog	Structural analog of modafinil with unknown precise mechanism in humans
no_human_trials	No published clinical trials in humans; anecdotal evidence only
research_chemical_status	Sold exclusively as a research chemical; no pharmaceutical approval
US legal status	Not FDA-approved in the US. Sold as a research chemical online. Regulatory status is undefined in most jurisdictions; not federally scheduled. Legal status varies by country and is evolving.

What is Flmodafinil?

Flmodafinil is a structural analog of modafinil, a wakefulness-promoting agent. It is designed to enhance alertness and cognitive function via dopamine and norepinephrine modulation, though precise mechanisms in humans are not fully characterized.

How it works

Dopamine and norepinephrine modulator with proposed reuptake inhibition and possible receptor effects. Mechanism in humans unclear; animal data suggest effects on reward and arousal circuits.

Background & history

Synthetic modafinil analog developed in research laboratories and research-chemical supply chains. Emerged online in 2000s as a modafinil alternative with purported longer duration; no pharmaceutical development history.

What the research says

Limited published human studies; most evidence is anecdotal from users and animal models. Animal studies suggest dopamine reuptake inhibition and norepinephrine modulation. Fewer controlled clinical trials than modafinil. Evidence for cognitive enhancement is sparse and not robustly validated.

Reported effects

Reported wakefulness promotion and fatigue reduction
Anecdotal reports of enhanced focus and concentration
Animal studies suggest dopamine-enhancing effects
Reported improvements in motivation and productivity (user reports)
Theoretical potential for cognitive enhancement via monoamine modulation

Dosing & administration (informational)

Harm-reduction information only: user reports vary widely; no validated dosing exists. Underground sources recommend doses lower than modafinil, but evidence is anecdotal.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Limited controlled human safety data; poorly characterized pharmacokinetics in humans
Potential for stimulant-related side effects (anxiety, insomnia, tachycardia, elevated blood pressure)
Quality of research-chemical sources is highly variable and often unverified
Unknown long-term effects and dependence potential
Contamination risk in unregulated supply chains

Drug & supplement interactions

Other stimulants and psychostimulants (additive cardiovascular and CNS effects)
Medications affecting dopamine or norepinephrine (interaction profile unclear)
Antidepressants and serotonergics (potential for serotonin syndrome at higher doses)

Who should avoid it

Concurrent stimulant use (excessive cardiovascular stress)
Evening dosing (severe insomnia likely)
High-dose escalation without monitoring (unknown long-term toxicity)
Individuals with baseline hypertension, arrhythmia, or coronary disease (stimulant risks)

How it is commonly combined

Stacking with other wakefulness-promoting or dopaminergic agents increases side-effect burden and unknown interaction risks.

Legal & regulatory. Not FDA-approved in the US. Sold as a research chemical online. Regulatory status is undefined in most jurisdictions; not federally scheduled. Legal status varies by country and is evolving.

Quality & harm reduction

D
e
m
a
n
d
t
h
i
r
d
-
p
a
r
t
y
C
o
A
v
e
r
i
f
y
i
n
g
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
;
f
l
m
o
d
a
f
i
n
i
l
s
o
u
r
c
e
s
a
r
e
r
a
r
e
a
n
d
o
f
t
e
n
u
n
t
e
s
t
e
d
.
P
r
e
f
e
r
s
u
p
p
l
i
e
r
s
w
i
t
h
t
r
a
n
s
p
a
r
e
n
t
s
y
n
t
h
e
s
i
s
d
o
c
u
m
e
n
t
a
t
i
o
n
a
n
d
c
o
n
s
i
s
t
e
n
t
a
n
a
l
y
t
i
c
a
l
m
e
t
h
o
d
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

How does flmodafinil compare to modafinil?

Both are wakefulness-promoting agents with similar mechanisms. Flmodafinil is a structural analog, but direct clinical comparisons are lacking. Reported potency and duration differ among users.

Is flmodafinil approved by any regulatory agency?

No major regulatory agency (FDA, EMA) has approved flmodafinil. It is sold exclusively as a research chemical.

What are the side effects of flmodafinil?

Reported side effects are similar to modafinil and other stimulants: anxiety, insomnia, headache, elevated heart rate. Long-term effects are unknown.

How long does flmodafinil last?

User reports suggest longer duration than modafinil, but no pharmacokinetic studies confirm this. Estimates range from 10-15 hours anecdotally.

References & further reading

A
n
i
m
a
l
d
o
p
a
m
i
n
e
a
n
d
n
o
r
e
p
i
n
e
p
h
r
i
n
e
-
m
o
d
u
l
a
t
i
o
n
r
e
s
e
a
r
c
h
;
m
o
d
a
f
i
n
i
l
-
a
n
a
l
o
g
p
h
a
r
m
a
c
o
l
o
g
y
;
u
s
e
r
-
c
o
m
m
u
n
i
t
y
r
e
p
o
r
t
s
;
l
i
m
i
t
e
d
W
e
s
t
e
r
n
c
l
i
n
i
c
a
l
p
s
y
c
h
o
p
h
a
r
m
a
c
o
l
o
g
y
s
o
u
r
c
e
s
.